Track topics on Twitter Track topics that are important to you
Cycle and Diplomat have entered into an agreement where Diplomat is the exclusive Specialty Pharmacy provider. NityrTM has recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Hereditary Tyrosinemia type-1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
HT-1 patients treated with NityrTM will benefit from the services of Diplomat's Rare Disease Center of Excellence - a team of specialists who serve the unique needs of rare disease populations. Diplomat’s Rare Disease Center of Excellence will also manage Cycle’s custom-built NityrTM Patient Support Program.
Bioequivalent to the current nitisinone capsule, NityrTM is the first treatment for HT-1 that does not require refrigeration and can be administered with or without food. NityrTM can provide treatment for patients from infancy to adulthood. NityrTM is available as an easy to swallow, small tablet and can also be disintegrated and administered in an oral syringe, which is ideal for paediatric patients.
“Working with a top-class player like Diplomat is consistent with our view that HT-1 patients and caregivers should be provided with the best product and the best service. We look forward to working with Diplomat to deliver the benefits of NityrTM to the HT-1 community,” said Antonio Benedetti, CEO, Cycle Pharmaceuticals.
Available in three strengths, 2 mg, 5 mg and 10 mg, NityrTM tablets are manufactured in Switzerland.
In clinical trials, NityrTM tablets have an established safety profile with warnings and precautions as follows:
There are no contraindications for NityrTM tablets, however, you should consult your Doctor prior to taking this medication. For full prescribing information on NityrTM, please visit www.nityr.us.
Hereditary Tyrosinemia type-1 (HT-1) is a rare and serious inherited metabolic disease caused by the inability to metabolise the amino acid tyrosine. Left untreated, HT-1 can cause hepatic, renal and peripheral nerve damage. HT-1 affects at least 1 in 100,000 patients worldwide, with approximately 150 patients in the United States.
About Cycle Pharmaceuticals, the commitment to HT-1 and NityrTM
Cycle Pharmaceuticals is committed to changing the way that HT-1 is treated and managed around the world. Cycle Pharmaceuticals has worked for more than four years closely with physicians and patient groups to reduce the impact that HT-1 treatment has on patients’ lives. NityrTM is the first formulation of nitisinone treatment that does not require refrigeration (removing the need of a cold chain transportation and storage) and can be taken with or without food, representing a significant improvement from previous treatments for patients and caregivers.
NityrTM should be taken in conjunction with a controlled diet and under the supervision of a healthcare professional.
Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services - helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit www.diplomat.is.
FOR FURTHER INFORMATION AND INTERVIEWS PLEASE CONTACT
Paula Bekinschtein, +44 1223 803 636 (GMT)
Global Marketing Manager
Company Site: www.cyclepharma.com
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...